These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 30929275)

  • 21. Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary.
    Tun N; Shibata Y; Soe MT; Htun MW; Koji T
    Histochem Cell Biol; 2019 Apr; 151(4):291-303. PubMed ID: 30511269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
    Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
    Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry.
    Naldi M; Andrisano V; Fiori J; Calonghi N; Pagnotta E; Parolin C; Pieraccini G; Masotti L
    J Chromatogr A; 2006 Sep; 1129(1):73-81. PubMed ID: 16887128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suberoylanilide hydroxamic acid, a novel histone deacetylase inhibitor, improves the development and acetylation level of miniature porcine handmade cloning embryos.
    Sun JM; Cui KQ; Li ZP; Lu XR; Xu ZF; Liu QY; Huang B; Shi DS
    Reprod Domest Anim; 2017 Oct; 52(5):763-774. PubMed ID: 28432707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic Acid Increases Histone Acetylation and Alters Gene Expression in the Donor Cells But Does Not Improve the In Vitro Developmental Competence of Buffalo (Bubalus bubalis) Embryos Produced by Hand-Made Cloning.
    Selokar NL; Saini M; Agrawal H; Palta P; Chauhan MS; Manik R; Singla SK
    Cell Reprogram; 2017 Feb; 19(1):10-18. PubMed ID: 28055238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
    Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
    BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
    Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
    J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
    Georgoff PE; Nikolian VC; Bonham T; Pai MP; Tafatia C; Halaweish I; To K; Watcharotone K; Parameswaran A; Luo R; Sun D; Alam HB
    Clin Pharmacokinet; 2018 Feb; 57(2):209-219. PubMed ID: 28497259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
    Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
    Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
    Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
    Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
    Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H
    Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.
    Bartels M; Geest CR; Bierings M; Buitenhuis M; Coffer PJ
    Haematologica; 2010 Jul; 95(7):1052-60. PubMed ID: 20107159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
    Carlisi D; Vassallo B; Lauricella M; Emanuele S; D'Anneo A; Di Leonardo E; Di Fazio P; Vento R; Tesoriere G
    Int J Oncol; 2008 Jan; 32(1):177-84. PubMed ID: 18097557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors.
    Bhat J; Oberg HH; Kabelitz D
    Cell Immunol; 2015 Jul; 296(1):50-6. PubMed ID: 25708484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of histone deacetylase inhibitors to examine the roles of bromodomain and histone acetylation in p300-dependent gene expression.
    Chen J; Li Q
    Methods Mol Biol; 2013; 977():353-7. PubMed ID: 23436376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.